- Home
- NYXH vs NVCT Comparison
NYXH vs NVCT Comparison
Compare NYXH & NVCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NYXH | NVCT |
|---|---|---|
| Founded | 2009 | 2020 |
| Country | Belgium | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 188.1M | 197.0M |
| IPO Year | 2021 | 2022 |
Fundamental Metrics
Financial Performance| Metric | NYXH | NVCT |
|---|---|---|
| Price | $4.66 | $7.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $12.67 | ★ $15.33 |
| AVG Volume (30 Days) | 46.3K | ★ 94.5K |
| Earning Date | 11-13-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,616,215.00 | N/A |
| Revenue This Year | $79.25 | N/A |
| Revenue Next Year | $297.08 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 10.96 | N/A |
| 52 Week Low | $4.35 | $4.44 |
| 52 Week High | $11.87 | $11.52 |
Technical Indicators
Market Signals| Indicator | NYXH | NVCT |
|---|---|---|
| Relative Strength Index (RSI) | 41.63 | 74.59 |
| Support Level | $4.69 | $6.47 |
| Resistance Level | $4.93 | $7.77 |
| Average True Range (ATR) | 0.20 | 0.42 |
| MACD | 0.01 | 0.13 |
| Stochastic Oscillator | 20.59 | 95.96 |
Price Performance
Historical ComparisonAbout NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.
About NVCT Nuvectis Pharma Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.